டொனால்ட் ம்க்க்யாஃப்‌ரீ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டொனால்ட் ம்க்க்யாஃப்‌ரீ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டொனால்ட் ம்க்க்யாஃப்‌ரீ Today - Breaking & Trending Today

Resverlogix Corp: Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada

Resverlogix's Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease Apabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placebo


Article content
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “
Novel Therapeutic Options for Cardiovascular Disease with CKD”.
The publication can be viewed HERE, and the accompanying editorial HERE.
“To my knowledge this is the first time that a cardiovascular risk reducing intervention – apabetalone – has shown such an improvement in clinical outcomes in patients with chronic kidney disease (CKD) – defined a ....

Reggio Calabria , United States , Francesca Mallamaci , Donald Mccaffrey , Grande Ospedale Metropolitano , Carmine Zoccali , Kam Kalantar Zadeh , Resverlogix Corp , Toronto Stock Exchange , University Of California Irvine , Nephrology Division , Betonmace Clinical Steering Committee , Major Adverse Cardiovascular Events , Chronic Kidney Disease , Recent Acute Coronary Syndrome , Clinical Journal , American Society , Therapeutic Options , Cardiovascular Disease , California Irvine , Steering Committee , Heart Failure , Kidney Disease , Therapy Designation , ரெஜியோ கலாப்ரியா , ஒன்றுபட்டது மாநிலங்களில் ,

Resverlogix's Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Resverlogix CorpApril 27, 2021 GMT
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial ”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “ ....

Reggio Calabria , United States , Francesca Mallamaci , Donald Mccaffrey , Grande Ospedale Metropolitano , Carmine Zoccali , Kam Kalantar Zadeh , Resverlogix Corp , Toronto Stock Exchange , University Of California Irvine , Nephrology Division , Betonmace Clinical Steering Committee , Major Adverse Cardiovascular Events , Chronic Kidney Disease , Recent Acute Coronary Syndrome , Controlled Trial , Clinical Journal , American Society , Therapeutic Options , Cardiovascular Disease , California Irvine , Steering Committee , Heart Failure , Kidney Disease , Therapy Designation , ரெஜியோ கலாப்ரியா ,

Resverlogix's Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease Toronto Stock Exchange:RVX


Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Apabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placebo
April 27, 2021 13:41 ET
| Source:
Resverlogix Corp
Resverlogix Corp
Calgary, Alberta, CANADA
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. ( Resverlogix or the Company ) (TSX:RVX) announced today the recent publication of an article titled: “
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same j ....

Reggio Calabria , United States , Francesca Mallamaci , Donald Mccaffrey , Grande Ospedale Metropolitano , Carmine Zoccali , Kam Kalantar Zadeh , Resverlogix Corp , Toronto Stock Exchange , University Of California Irvine , Nephrology Division , Betonmace Clinical Steering Committee , Major Adverse Cardiovascular Events , Chronic Kidney Disease , Recent Acute Coronary Syndrome , Clinical Journal , American Society , Therapeutic Options , Cardiovascular Disease , California Irvine , Steering Committee , Heart Failure , Kidney Disease , Therapy Designation , Toronto Stock Exchange Rvx , Resverlogix Corp ,